Welcome to our dedicated page for Cardinal Health news (Ticker: CAH), a resource for investors and traders seeking the latest updates and insights on Cardinal Health stock.
Cardinal Health, Inc. distributes pharmaceuticals and specialty products and manufactures and distributes medical, laboratory, home-health and direct-to-patient products and services. The company also operates nuclear pharmacies and manufacturing facilities and provides performance and data solutions for healthcare customers.
Recurring company updates cover financial results and fiscal outlooks, dividend actions, share repurchases, debt activity, segment performance in Global Medical Products and Distribution, at-Home Solutions, Nuclear and Precision Health Solutions and OptiFreight Logistics. Other developments include biosimilars and advanced-therapy research reports, Actinium-225 production capacity for radiopharmaceutical applications, and board governance changes.
Cardinal Health (NYSE: CAH) will release its first-quarter financial results for fiscal year 2021 on November 5, ahead of market opening. A webcast discussing these results will commence at 8:30 a.m. Eastern. Investors can access the webcast and presentation slides through the company's Investor Relations page without an access code. The presentation materials will remain available until November 4, 2021. Cardinal Health has nearly 100 years of experience, providing integrated healthcare solutions globally, enhancing supply chain efficiency for medical products, pharmaceuticals, and cost-effective solutions.
Cardinal Health (NYSE: CAH) has elected Sheri Edison as an independent director, effective September 1, 2020. With extensive experience as a legal executive in medical devices and packaging, Ms. Edison aims to enhance the board's capabilities in legal, regulatory compliance, and corporate governance. Currently serving as General Counsel for Amcor, she has held senior positions at Bemis and Hill-Rom Holdings. Her appointment brings valuable insight to the board, complementing current expertise in healthcare.
Cardinal Health (NYSE: CAH) reported Q4 FY2020 revenues of $36.7 billion, down 2% year-over-year, with GAAP operating earnings of $270 million. The COVID-19 pandemic negatively impacted earnings by approximately $130 million. Fiscal year revenues rose 5% to $152.9 billion, but the company reported a GAAP operating loss of $4.1 billion primarily due to opioid litigation. Non-GAAP EPS for Q4 was $1.04, slightly down from last year. For FY2021, non-GAAP EPS guidance is between $5.25 - $5.65, accounting for continued COVID-19 headwinds.
Cardinal Health (NYSE: CAH) will report its fourth-quarter and year-end financial results for FY 2020 on August 6, prior to NYSE trading. A webcast discussing these results will be held at 8:30 a.m. Eastern. The company has a strong presence in the healthcare sector, focusing on providing customized solutions for various healthcare entities. Investors can access the webcast and slides through the Investor Relations page without needing an access code. Replay will be available until August 5, 2021.
Cardinal Health (NYSE: CAH) announced the election of David C. Evans as an independent director, effective July 1. Mr. Evans brings extensive financial expertise and operational experience, having served as interim CFO of Cardinal Health and CFO at Battelle Memorial Institute and Scotts MiracleGro. His board roles include positions at Scotts MiracleGro and the Siegel Rare Neuroimmune Association. The board chair, Gregory Kenny, expressed confidence in Evans' leadership during periods of change, emphasizing the importance of his insights for future growth strategies.